LWA
ACAD icon

Lenox Wealth Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Lenox Wealth Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$4K Sell
150
-50
-25% -$1.21K ﹤0.01% 574
2021
Q4 		$5K Buy
+200
New +$4.02K ﹤0.01% 592

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Lenox Wealth Advisors's ACAD Position: Q1 2022 in Review

Lenox Wealth Advisors reduced its Acadia Pharmaceuticals (ACAD) stake by 25% in Q1 2022, selling an estimated $1.21K and leaving 150 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #574.

Lenox Wealth Advisors first reported a position in ACAD in Q4 2021 and has held it in 2 quarters since. The position peaked at $5K in Q4 2021. 263 funds tracked by Wall St. Rank hold ACAD as of Q1 2022.

  • Lenox Wealth Advisors held 150 shares of Acadia Pharmaceuticals worth $4K as of Q1 2022.
  • Lenox Wealth Advisors sold 50 Acadia Pharmaceuticals shares in Q1 2022, an estimated $1.21K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Lenox Wealth Advisors's portfolio in Q1 2022, its #574 holding.
  • Lenox Wealth Advisors first reported a position in Acadia Pharmaceuticals in Q4 2021 and has held it in 2 quarters since.
  • Lenox Wealth Advisors's Acadia Pharmaceuticals position peaked at $5K in Q4 2021.
  • 263 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2022.

Based on Lenox Wealth Advisors's 13F filing for Q1 2022, filed 14 Apr 2022.